AU2007264205B2 - Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails - Google Patents

Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails Download PDF

Info

Publication number
AU2007264205B2
AU2007264205B2 AU2007264205A AU2007264205A AU2007264205B2 AU 2007264205 B2 AU2007264205 B2 AU 2007264205B2 AU 2007264205 A AU2007264205 A AU 2007264205A AU 2007264205 A AU2007264205 A AU 2007264205A AU 2007264205 B2 AU2007264205 B2 AU 2007264205B2
Authority
AU
Australia
Prior art keywords
vaccine according
epitopes
protein
peptides
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2007264205A
Other languages
English (en)
Other versions
AU2007264205A1 (en
Inventor
Claus Aagaard
Peter Andersen
Jes Dietrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of AU2007264205A1 publication Critical patent/AU2007264205A1/en
Application granted granted Critical
Publication of AU2007264205B2 publication Critical patent/AU2007264205B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007264205A 2006-06-28 2007-06-26 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails Expired - Fee Related AU2007264205B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600861 2006-06-28
DKPA200600861 2006-06-28
PCT/DK2007/000312 WO2008000261A2 (en) 2006-06-28 2007-06-26 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Publications (2)

Publication Number Publication Date
AU2007264205A1 AU2007264205A1 (en) 2008-01-03
AU2007264205B2 true AU2007264205B2 (en) 2013-04-18

Family

ID=38845996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007264205A Expired - Fee Related AU2007264205B2 (en) 2006-06-28 2007-06-26 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails

Country Status (11)

Country Link
US (2) US8105614B2 (enExample)
EP (3) EP2040745B1 (enExample)
JP (1) JP5165681B2 (enExample)
KR (1) KR20090024292A (enExample)
AU (1) AU2007264205B2 (enExample)
BR (1) BRPI0713978A2 (enExample)
CA (1) CA2654271A1 (enExample)
DK (1) DK2040745T3 (enExample)
ES (1) ES2400531T3 (enExample)
RU (1) RU2490024C2 (enExample)
WO (1) WO2008000261A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6480999A (en) 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
PL2167124T3 (pl) * 2007-06-29 2012-12-31 Statens Seruminstitut Zastosowanie monomikoliloglicerolu (MMG) jako adiuwantu
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
HUE030520T2 (en) * 2008-11-28 2017-05-29 Statens Seruminstitut Optimized influenza vaccines
KR20170072366A (ko) * 2009-04-24 2017-06-26 스태튼스 세룸 인스티튜트 재활성화를 예방하기 위한 결핵 백신
CA2769996C (en) * 2009-11-05 2018-06-12 The United States Of America As Represented By The Secretary Of The Na Plasmodium falciparum sporozoite and liver stage antigens
WO2011063133A1 (en) * 2009-11-18 2011-05-26 Auburn University LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
DK3079716T3 (da) * 2013-12-13 2019-08-19 Us Health Multiepitop-tarp-peptidvaccine og anvendelser deraf.
BR112016023778A2 (pt) 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
CN117064854A (zh) * 2023-08-14 2023-11-17 广州谦毅生物医药有限公司 一种卡瓦脂质体的制备技术

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
PT992580E (pt) * 1993-11-04 2005-07-29 Innogenetics Nv Epitopos para celulas t humanas imunodominantes do virus da hepatite c
KR100797876B1 (ko) * 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
AU779978B2 (en) * 1999-10-07 2005-02-24 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
ATE406874T1 (de) 2004-07-07 2008-09-15 Statens Seruminstitut Zusammensetzungen und verfahren zur stabilisierung von adjuvans-formulierungen auf lipid-basis unter verwendung von glykolipiden
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
FR2873467A1 (fr) 2004-07-26 2006-01-27 Proton World Internatinal Nv Enregistrement d'une cle dans un circuit integre
ES2425576T3 (es) * 2006-01-26 2013-10-16 Zoetis P Llc Composiciones coadyuvantes glucolipídicas novedosas
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016163A2 (en) * 1999-08-27 2001-03-08 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response

Also Published As

Publication number Publication date
AU2007264205A1 (en) 2008-01-03
US20120156282A1 (en) 2012-06-21
JP5165681B2 (ja) 2013-03-21
WO2008000261A2 (en) 2008-01-03
JP2009541373A (ja) 2009-11-26
EP2402024A1 (en) 2012-01-04
EP2040745A2 (en) 2009-04-01
BRPI0713978A2 (pt) 2012-11-27
DK2040745T3 (da) 2013-03-18
KR20090024292A (ko) 2009-03-06
EP2402023A1 (en) 2012-01-04
CA2654271A1 (en) 2008-01-03
EP2040745B1 (en) 2012-12-05
US8105614B2 (en) 2012-01-31
WO2008000261A3 (en) 2008-03-20
RU2490024C2 (ru) 2013-08-20
US20080008724A1 (en) 2008-01-10
RU2009102389A (ru) 2010-08-10
ES2400531T3 (es) 2013-04-10

Similar Documents

Publication Publication Date Title
EP2040745B1 (en) Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
EP1523331B1 (en) Therapeutic tb vaccine
AU2010238943B9 (en) A tuberculosis TB vaccine to prevent reactivation
US7037510B2 (en) Hybrids of M. tuberculosis antigens
US10004793B2 (en) M.tuberculosis vaccines
Golovliov et al. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis
JP2019163253A (ja) クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
WO2002004018A2 (en) Mid-life vaccine and methods for boosting anti-mycobacterial immunity
ES2285466T3 (es) Combinaciones adyuvantes de liposomas y lipidos de micobacterias para composiciones de inmunizacion y vacunas.
WO2005061534A2 (en) Improved tuberculosis vaccines
WO1999061068A1 (en) Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
CN102488898B (zh) 龋齿疫苗及制备方法
Baldwin Novel vaccine approaches against aerogenic infection with Mycobacterium tuberculosis
Guan Development of liposomal antigen delivery system for synthetic muc1 peptides

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee